PriceTargets.com logo

RayzeBio - RYZB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $31.33
  • Forecasted Upside: -49.86%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$62.49 As of 02/26/2024 01:00 AM ET
+0 (0.00%)
Get New RayzeBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RYZB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RYZB

Analyst Price Target is $31.33
▼ -49.86% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for RayzeBio in the last 3 months. The average price target is $31.33, with a high forecast of $35.00 and a low forecast of $29.00. The average price target represents a -49.86% upside from the last price of $62.49.

This chart shows the closing price for RYZB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in RayzeBio. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/26/2023William BlairDowngradeOutperform ➝ Market PerformN/A
10/11/2023Evercore ISIInitiated CoverageOutperformLow
10/10/2023Truist FinancialInitiated CoverageBuy$29.00Low
10/10/2023JPMorgan Chase & Co.Initiated CoverageOverweight$30.00Low
10/10/2023Jefferies Financial GroupInitiated CoverageBuy$35.00Low
10/6/2023William BlairInitiated CoverageOutperformLow
(Data available from 4/28/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 5 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
RayzeBio logo
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Read More

Today's Range

Now: $62.49
Low: $62.49
High: $62.49

50 Day Range

MA: $62.47
Low: $62.27
High: $62.49

52 Week Range

Now: $62.49
Low: $17.95
High: $62.51

Volume

N/A

Average Volume

553,592 shs

Market Capitalization

$3.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of RayzeBio?

The following Wall Street analysts have issued reports on RayzeBio in the last twelve months: Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Truist Financial Co., and William Blair.
View the latest analyst ratings for RYZB.

What is the current price target for RayzeBio?

3 Wall Street analysts have set twelve-month price targets for RayzeBio in the last year. Their average twelve-month price target is $31.33, suggesting a possible downside of 49.9%. Jefferies Financial Group Inc. has the highest price target set, predicting RYZB will reach $35.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $29.00 for RayzeBio in the next year.
View the latest price targets for RYZB.

What is the current consensus analyst rating for RayzeBio?

RayzeBio currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RYZB.

What other companies compete with RayzeBio?

Other companies that are similar to RayzeBio include Biohaven, Iovance Biotherapeutics, Amicus Therapeutics, Integer and CymaBay Therapeutics. Learn More about companies similar to RayzeBio.

How do I contact RayzeBio's investor relations team?

The company's listed phone number is 619-937-2754. The official website for RayzeBio is rayzebio.com. Learn More about contacing RayzeBio investor relations.